Journal
JOURNAL OF CLINICAL MEDICINE
Volume 9, Issue 11, Pages -Publisher
MDPI
DOI: 10.3390/jcm9113599
Keywords
non-infectious uveitis; biotherapy; anti-TNF-α (anti-tumor necrosis factor alpha) agent; tocilizumab; Janus Associated Kinase (JAK) inhibitors
Categories
Ask authors/readers for more resources
Non-infectious uveitis (NIU) represents one of the leading causes of blindness in developed countries. The therapeutic strategy aims to rapidly control intra-ocular inflammation, prevent irremediable ocular damage, allow corticosteroid sparing and save the vision, and has evolved over the last few years. Anterior NIU is mostly managed with topical treatment in adults. However, for intermediate, posterior and pan-uveitis, notably when both eyes are involved, systemic treatment is usually warranted. Biotherapies are recommended in case of inefficacy or non-tolerance of conventional immunosuppressive drugs in non-anterior NIU. Anti-tumor necrosis factor alpha (anti-TNF-alpha) agents are by far the most widely used, especially adalimumab (ADA) and infliximab (IFX). In case of sight-threatening uveitis in Behcet's disease or in case of risk of severe recurrences, respectively IFX and ADA may be recommended as first-line therapy. Many questions are left unanswered; how long to treat NIU, how to discontinue anti-TNF-alpha agents, what biologic to use in case of anti-TNF-alpha failure? The objective of this review is to present an updated overview of knowledge on the use of biological treatments in NIU.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available